Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | HPGD | P15428 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.64 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.61 |
| ▸ | USP2 | O75604 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | XBP1 | P17861 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11939089 | 0.85 | CSNK2A1 (0.67) | KDM4EKMT2AHPGDALDH1A1MEN1 | |
| SCHEMBL3333973 | 0.81 | CSNK2A1 (0.84) | KDM4EKMT2AHPGDALDH1A1MEN1 | |
| SCHEMBL291505 | 0.80 | KDM4E (0.68) | KDM4EKMT2AHPGDALDH1A1MEN1 | |
| SCHEMBL11940597 | 0.80 | CSNK2A1 (0.79) | KDM4EKMT2AHPGDALDH1A1MEN1 | |
| SCHEMBL3334412 | 0.79 | CSNK2A1 (0.66) | KDM4EKMT2AHPGDALDH1A1MEN1 | |
| SCHEMBL291750 | 0.79 | KDM4E (0.69) | KDM4EKMT2AHPGDALDH1A1MEN1 | |
| SCHEMBL3333345 | 0.78 | CSNK2A1 (0.64) | KDM4EKMT2AHPGDALDH1A1MEN1 | |
| SCHEMBL12288530 | 0.78 | CSNK2A1 (0.68) | KDM4EKMT2AHPGDALDH1A1MEN1 | |
| SCHEMBL3333434 | 0.77 | CSNK2A1 (0.60) | KDM4EKMT2AHPGDALDH1A1MEN1 | |
| SCHEMBL3331873 | 0.77 | CSNK2A1 (0.67) | KDM4EKMT2AHPGDALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | M.D. ANDERSON CANCER CENTER (US) | 2012-11-29 | — | — | US | disclosed |
| US-8268809-B2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | EMORY UNIVERSITY (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268809-B2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | EMORY UNIVERSITY (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | EMORY UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | EMORY UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100144738-A1 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-10 | — | — | US | disclosed |
| US-20100144738-A1 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-10 | — | — | US | disclosed |
| US-20100144738-A1 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-10 | — | — | US | disclosed |
| WO-2008030744-A2 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008030744-A2 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | MAP3K1, MAP3K2, MAP3K6 | KDM4E 1924/4885KMT2A 1524/4885HPGD 3665/4885 |
| US-20100144738-A1 | INHIBITORS OF C-MET AND USES THEREOF | MET, HGF, HGFAC | KDM4E 1415/4885KMT2A 1909/4885HPGD 3888/4885 |
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | MAP3K1, MAP3K2, MAP3K6 | KDM4E 1924/4885KMT2A 1524/4885HPGD 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.